# Independent product acceptance assessment

**CancerOS is not ready for acceptance as the originally specified integrated research prototype.** Its strongest delivered experiences are a read-only synthetic geometry demonstration and an administrator workflow for pseudonymous profiles and clinical records. They do not yet compose into authentic MRI → observed twin → hypothetical scenarios → synchronized clinical exploration → grounded interpretation.

This conclusion comes from original specifications, fresh code inspection, a fresh production build and current browser attempts. Previous review conclusions were excluded. This is an AI-led expert inspection, with bounded specialist-agent passes, not a human multidisciplinary consultation or a participant study.

## What the product was intended to be

CancerOS should help researchers inspect how image-derived lesion geometry and available clinical observations change over time, while keeping actual evidence and hypothetical evolution unmistakably separate. It should feel like one case-centered research instrument. It is not a diagnostic or treatment-selection service.

| Original product question | Specification-derived answer |
| --- | --- |
| Fundamental problem | Bring imaging, clinical history, hypothetical evolution and evidence-linked explanations into one inspectable temporal case. PRD §§1–3, UJ-01–08, pp9–15. |
| Users | Research viewers/judges, editors/presenters and administrators with different permitted actions. SPEC-009 §3 p2; SPEC-008 §16 p15. |
| Principal journeys | Import/load a case, inspect geometry, generate scenarios, navigate states, add observations, inspect findings and evaluate limits. PRD §5 pp9–15. |
| Researcher inputs | Source-backed profile/clinical facts, dates or explicit missing time, quantities with units, records/notes, examination metadata and compatible imaging; supported scenario assumptions. PRD FR-001–028 pp15–17; SPEC-009 §§4.5–4.8 pp5–6. |
| Derived outputs | Deterministic measurements, source-linked meshes, immutable states, reproducible synthetic follow-ups, calculated changes and grounded descriptions. PRD FR-008–050 pp16–18. |
| Imaging ingestion | Authorized source and identity linkage, spatial QC, meaningful verified mask, measurement preview and confirmed baseline. PRD UJ-02 pp10–11; SPEC-005 §§7–13. |
| Twin visualization | A physically scaled, rotatable lesion with time, source, measurement and supported context, connected to the selected state. SPEC-009 §§4.3/7–8 pp3/8–9. |
| Hypothetical evolution | Five families; one shared authentic observed baseline plus at least three generated follow-ups per family; assumptions and publication are explicit. PRD FR-017–028; SPEC-004; SPEC-009 §4.5. |
| Clinical relationship | Each modality retains its own collection time and provenance; new labs do not imply new imaging. SPEC-009 §§5/8–9 pp7/9–10. |
| AI responsibility | Explain returned evidence, identify gaps and compare deterministic facts; never invent measurements. A truthful fallback remains usable. SPEC-006 §§10–14; PRD FR-045; COS-HACK-001 §§5/10 separately requires substantive eligible Meta use. |
| Finished experience | Case library → coherent case shell, prominent 3D, synchronized timeline/charts and contextual Findings/Records/Evidence, with clear loading, unavailable and recovery states. SPEC-009 §§3–4/11–13. |
| Minimum acceptable prototype | Approved authentic imaging/mask/3D, five four-position scenario families, clinical updates, evidence-linked interpretation, real repeated-imaging demonstration and actual evaluation. PRD §14 pp31–32, AC-01–12 pp32–35; SPEC-011 §11 p6. |

Imported reference masks are an acceptable P0 path. Automated segmentation, trained forecasting, a full radiology workstation and simultaneous multi-branch comparison must not become unnecessary prerequisites. Two-state comparison is P0; simultaneous branch comparison is P1 (SPEC-009 §2 p1).

One source tension remains explicit: SPEC-006 §21 p32 names Meta interpretation as P0, whereas later SPEC-012 B22/§7 permits a conditional provider and a deterministic or approved saved fallback. The fallback can preserve the research journey; it does not establish full original AI or hackathon completion. No owner adoption record resolving that broader claim was inferred.

## What actually exists

The fresh build exposes pages for cases, case detail, twin, states, charts, observation timeline, simulation, insights, evaluation, guided demo, admin, activity, mesh preview and demo. Modular FastAPI services, private SQL/object persistence, imaging geometry, measurement, mesh generation and five scenario engines exist.

In the artificial authenticated browser continuation, two cases were created; case A was reopened, its profile revised, a 12.3 g/dL artificial lab saved and corrected to 12.4 g/dL. The corrected value appeared in charts. Case B remained empty. This is real UI-to-API persistence in a **test-mode artificial environment**, not proof of authentic-source operation.

The opt-in demo renders a labeled geometric phantom, four discrete states in each of five families, state-linked measured volume and a local template explanation. It is coherent enough for an engineering demonstration. It neither imports patient MRI nor lets a researcher run a new simulation. Its baseline is synthetic.

## Most consequential gaps

1. **Broken orchestration:** the scenario route discards context even when its URL contains a selected case. Insights requires a manually pasted state ID and sends bodies incompatible with backend contracts. Primary case-related navigation loses selection. These failures precede external access gates.
2. **Authentic-source capability is unfinished:** staging, annotation, baseline and publication paths remain explicitly fixture-limited. Closing rights/review paperwork alone cannot enable the required authentic workflow; a controlled implementation path is missing.
3. **Incomplete clinical workflow:** refresh can indefinitely block observation entry; editor permissions contradict the specified role model; correction lacks the required reason/review and retraction flow in this workspace. Saving records does not complete dependent-state publication.
4. **Missing administration and processing UI:** authenticated administrators still see a static import placeholder; Activity is also a placeholder. The UI cannot attach an examination or follow processing to a published baseline.
5. **Weak evidence delivery:** evaluation uses hardcoded fixture claims rather than versioned reports and even relabels original UX acceptance IDs. Genuine longitudinal evidence, qualified scientific review and live application Meta integration remain unverified or unavailable.
6. **Authorization exception:** saved interpretation detail ignores the patient path and uses project membership only. A fabricated function probe demonstrates metadata retrieval without a patient-grant check. Raw clinical prose disclosure was not demonstrated.

## Separate acceptance outcomes

| Dimension | Independent assessment |
| --- | --- |
| Product requirements | Partial; mandatory authentic and integrated workflows unmet |
| User journeys | Partial case/clinical success; end-to-end journey fails |
| UI/UX usability | Not ready for a first-time researcher without technical assistance |
| Visual design | Readable desktop foundations and a useful demo; excessive repeated technical copy, duplicate navigation and mobile entry-card failure |
| Case/clinical management | Functional artificial administrator slice, incomplete role/update/correction experience |
| Imaging | Significant processing code; no complete ordinary authentic import journey |
| 3D | Interactive phantom verified; authentic anatomical reconstruction not established |
| Longitudinal simulation | Engines exist; ordinary generation UI unusable; demo is prepared playback |
| Meta AI | Not integrated as a live application research agent; no live call made in this review |
| Engineering | Fresh build and 119 focused synthetic/unit checks pass; contract/route/ownership defects remain |
| Scientific integrity | Important provenance and geometry safeguards exist; no qualified clinical validation or authentic longitudinal acceptance |
| End-to-end readiness | Not accepted |

Engineering implementation is substantial but incomplete. Functional product completion and user-experience readiness are not achieved. Scientific validation is not established. Operational readiness is not established by local startup or test fixtures; deployed recovery, real roles, performance and release evidence remain separate.

Recover the existing modular product through the [prioritized plan](PRIORITIZED-PRODUCT-RECOVERY-PLAN.md): repair the connected journeys and contract drift first, implement controlled authentic onboarding next, then validate the actual scientific and operational release slice. A visual redesign alone will not close these gaps.
